Alcoholic Hepatitis - Pipeline Insight, 2024

This “Alcoholic Hepatitis- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alcoholic Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Alcoholic Hepatitis: Understanding

Alcoholic Hepatitis: Overview

Alcoholic hepatitis is an inflammatory condition of the liver caused by heavy alcohol consumption over an extended period of time. Ongoing alcohol use and binge drinking can both aggravate this condition. Continued drinking can lead to additional health conditions, such as cirrhosis, excessive bleeding, or even liver failure.

The most common sign of alcoholic hepatitis is yellowing of the skin and whites of the eyes (jaundice).Other signs and symptoms include loss of appetite, nausea and vomiting, abdominal tenderness, fever, often low grade, fatigue and weakness.

The diagnosis of alcoholic hepatitis include following tests:

• Blood tests, a complete blood count (CBC) screens for a variety of disorders, while liver function tests check specifically for elevated liver enzymes. Blood and urine (pee) alcohol screens, such as phosphatidyl ethanol and urine ethyl glucuronide, are becoming more common.
• Imaging tests to visualize your liver and look for signs of inflammation and damage, such as an ultrasound, Fibro Scan®, CT scan orMRI.
• Liver biopsy in which a sample of your liver tissue is examined in the lab. The sample is obtained through a hollow needle inserted into the liver.

There’s no medicine to treat alcohol-induced hepatitis directly. The only effective treatment is to quit drinking. However, it’s best to quit under medical supervision. Supplemental treatments may include:

Nutritional therapy: Both alcohol use and liver damage can cause malnutrition, due to appetite suppression, nausea and a reduced ability to metabolize nutrients. Malnutrition can contribute to poor recovery from these diseases. The healthcare provider may prescribe dietary changes and nutritional supplements to help recover, and sometimes appetite stimulants. In severe cases, they may treat the patient with enteral nutrition (tube feeding).- Short-term steroids: Healthcare providers may treat certain severe cases of alcohol-induced hepatitis temporarily with steroids to help reduce inflammation and encourage liver cells to regenerate.

Alcoholic Hepatitis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alcoholic Hepatitis pipeline landscape is provided which includes the disease overview and Alcoholic Hepatitis treatment guidelines. The assessment part of the report embraces, in depth Alcoholic Hepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alcoholic Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alcoholic Hepatitis R&D. The therapies under development are focused on novel approaches to treat/improve Alcoholic Hepatitis.

Alcoholic Hepatitis Emerging Drugs Chapters

This segment of the Alcoholic Hepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alcoholic Hepatitis Emerging Drugs

DUR-928: Durect DUR-928 is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication. DURECT is currently conducting a Phase IIb study (AHFIRM) in subjects with severe alcohol-associated hepatitis (also called Alcoholic Hepatitis or AH) to evaluate safety and efficacy of DUR-928 treatment. DUR-928 has been shown to inhibit the activity of DNMTs (DNMT-1, 3a and 3b), inhibiting DNA methylation, and upregulating expression of genes involved in signaling pathways associated with cell death, stress response, and lipid biosynthesis, which may ultimately result in increased cell survival, reduced inflammation, and decreasedlipotoxicity.

Canakinumab: Novartis Canakinumab is a licensed monoclonal antibody inhibitor of IL-1 and may consequently reverse the adverse effects of the cytokine in patients with this disorder. Therefore, the main objective of the Phase II ISAIAH trial is to explore the potential benefits of the IL-1ß antibody, Canakinumab (solution for injection), in the treatment of alcoholichepatitis.

Alcoholic Hepatitis: Therapeutic Assessment

This segment of the report provides insights about the different Alcoholic Hepatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Alcoholic Hepatitis

There are approx. 10+ key companies which are developing the therapies for Alcoholic Hepatitis. The companies which have their Alcoholic Hepatitis drug candidates in the most advanced stage, i.e. phase III include, Durect.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Alcoholic Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alcoholic Hepatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alcoholic Hepatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alcoholic Hepatitis drugs.

Alcoholic Hepatitis Report Insights

• Alcoholic Hepatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alcoholic Hepatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Alcoholic Hepatitis drugs?
• How many Alcoholic Hepatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alcoholic Hepatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alcoholic Hepatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alcoholic Hepatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis Pharmaceuticals
• Durect
• Intercept Pharmaceuticals
• Aldeyra Therapeutics
• Surrozen

Key Products

• Canakinumab
• DUR-928
• INT-787
• ADX-629
• SZN 043

This product will be delivered within 1-3 business days.